________________________________________________________________________________________________________________________________

© Wolf G Kroner 2018 Stefan Joachim OschmannPhilanthropy re-visited: Merck’s focus on Africa

August 2018.In recent years Merck has been significantly stepping up its engagement in Sub-Saharan Africa. Focus on neglected tropical diseases or drug donation programs are but two building blocks. What other diseases are relevant? A conversation about a longer term strategy which aims at creating win-win results for regional healthcare systems, patients, Western pharma industry objectives, as well as Merck’s own profitability. Stefan Oschmann, CEO and Chairman of the Executive Board Merck KGaA answers B2Bioworld’s questions in direct conversation. Includes prospects of African scientists to participate in the company’s Future Insight Prize programme. In addition, B2Bioworld offers independent background to interested readers.

If you like to read this article, you can purchase it now

Please notice, If you order by email from an organisation - for-profit or nonprofit alike - you must buy an organisation sharing license and cannot buy an individual license. However the organisation sharing license entitles you to share the article with up to four other individuals - provided you adhere to the Terms and Conditions which you agree with when purchasing articles of B2Bioworld.

Read Now - Please select your license (Prices incl. 7% VAT)
9 pages free of advertisement

Article free of advertisement
- Includes additional data collected by B2Bioworld, for example independent data on Schistosomiasis, praziquantel paediatric clinical trials Latin America, Ranking Access to Mediicines (20 top global companies), background to Future Insight Prize, Merck vs. MSD, Representatives of the London Declaration on Neglected Tropical Diseases January 2012.

Full Company License enquire here

Back to section

Related Editorial Articles

B2Bioworld offers you background information

Steering Health Data For or By? The User as Stakeholder, Expert, Citizen, Consumer, and Patient
Thomas Szucs, Chairman of Swiss Helsana Group on putting “big data” to work in insurance and healthcare

Adhering to Values Pays Off
Novartis continues to expand the biotech therapeutics pipeline / Focus on emerging markets

Systems Biology Applied
Rudi Balling, Director Luxembourg Centre for Systems Biomedicine on the Need of Systems Theory Thinking in Using Technologies and Pitfalls of Key Concepts

Metrics for Disease, Health, and Wellness
A systems look at DNA sequencing for personalized medicine by Leroy Hood, President Institute for Systems Biology, Seattle

CO2 as resource for specialty chemicals: What makes it difficult for industry?
Peter Nagler, Head of International Innovation, Evonik Industries anchors the topic in the company’s strategies to internationalise R&D, the position of the chemical industry and societal perspectives

Pharma Boost for Red Cross/Red Crescent’s Community Disease Prevention Programme

Improving the IP System on a global scale: A view from Japan
Sadao Nagaoka, Institute of Innovation Research, and Chief Policy Adviser to the Japanese Government

Plant Genetic Engineering:”It’s not as simple as Yes or No!”
Nobel Laureate Christiane Nüsslein-Volhard warns of GMO-populism and researchers not standing up

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, past Chief Technology Officer Life Sciences at Tecan and toady with Merck on electrowetting technology, blood diagnostic devices, weaknesses of competitors like Illumina, and prospects of clinical microfluidics

Transition Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Make or Break Drug Discovery and Biopharma of Merck Life Science
Andrew Bulpin, currently Global Head of Merck Millipore Process Solutions on strategy and the road ahead. Includes competitive ranking of Merck Life Science Division

Roche Ethiopia: Build-up of an emerging market

Opening up Emerging Markets for Rapid Diagnostics and Point-of-Care Assays
David Dolinger shares experience and insight. Do’s and don’ts in developing viable tests for medical, agricultural, or food diagnostics, and bringing these to low resource countries